# HUMAN HEALTH
# ONCOLOGY

SATT NORD
Technology Transfer Office

## KEY WORDS:

* Breast Cancer
* Chemotherapy
* Resistance
* Prognosis
* Companion Test


**YOUR CONTACT:**

**François-Xavier DENIMAL**
Business Developer
Tel: +33 6.13.84.36.28
**francois-xavier.denimal @sattnord.fr**


# New target to counter resistance mechanisms in breast cancer.

* The proposed technology can overcome the development of resistance to treatment in the case of breast cancer therapy failure (30% of cases) by blocking a newly identified tumor escape.
* This treatment strategy could be applied to other types of cancers:
    * ENT
    * Prostate
* A companion test was developed to orient and monitor treatment.



## BENEFITS:

*Identification of a new co-receptor of TrkA and a new signaling pathway which is associated with a tumor escape route.

* The presence of this coreceptor is a poor prognostic factor (Correlation of coreceptor expression levels with the grade of cancer by the method of Duolink in Immunohistochemistry)

Results achieved on Tissue Micro Array (TMA) representing a cohort of 40 patients.

The cohort will be expanded to 200 patients (results expected during Q1 2015 )

* Therapeutic strategy for chemo-resistant cancers (30% of cases) after treatment targeting tyrosine kinases (eg Lestaurtinib)
* Significant increase in life expectancy of the co-treated group (2 siRNAs) versus control groups (untreated, single treatment)

## APPLICATIONS:

* Treatment of Breast Cancer
* Potential treatment of other cancers (ENT, prostate ...)
* Companion test on different types of cancers

## DEVELOPMENT STATUS:

* Proof of concept on breast cancer.
* Companion test validated on breast cancer.
* Companion test being validated on ENT cancers and prostate cancer.
* In search of a partner for the development of a therapeutic molecule: (eg monoclonal antibodies)

## INTELLECTUAL PROPERTY:

* Patent filled on September 16, 2014


**SATT Nord**
2, rue du Priez - 59000 LILLE - France
+33 3 28 36 04 68 - lille@sattnord.fr



Reference: ProNGF - 10/2014 -